The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of an Austrian multicenter, noninterventional study

BACKGROUND: The pretreatment De Ritis ratio [aspartate transaminase (AST)/alanine transaminase (ALT)] has been shown to be an adverse prognostic marker in various cancer entities. However, its relevance to advanced pancreatic ductal adenocarcinoma (PDAC) has not yet been studied. In the present stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Riedl, Jakob Michael, Posch, Florian, Prager, Gerald, Eisterer, Wolfgang, Oehler, Leopold, Sliwa, Thamer, Wilthoner, Klaus, Petzer, Andreas, Pichler, Petra, Hubmann, Eva, Winder, Thomas, Burgstaller, Sonja, Korger, Markus, Andel, Johannes, Greil, Richard, Neumann, Hans-Joerg, Pecherstorfer, Martin, Philipp-Abbrederis, Kathrin, Djanani, Angela, Gruenberger, Birgit, Laengle, Friedrich, Wöll, Ewald, Gerger, Armin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153180/
https://www.ncbi.nlm.nih.gov/pubmed/32313566
http://dx.doi.org/10.1177/1758835919900872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153180/
https://www.ncbi.nlm.nih.gov/pubmed/32313566
http://dx.doi.org/10.1177/1758835919900872

Ejemplares similares